RxDoctor Payments Data

Jeffrey Tatar

Physician Assistant · Rochester, NYNPI 1245401348

Payments from drug & device makers

$3,767in general payments, 2019–2025

Across 53 payments — averaging $71.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$397
  • UCB, Inc.$312
  • Lilly USA, LLC$298
  • Galderma Laboratories, L.p.$251
  • Dermavant Sciences, Inc.$202
  • plus $637 from 6 others

What the payments were for

  • Consulting fees$1,06328%
  • Travel & lodging$1394%
  • Food & beverage$2,29561%
  • Education$2717%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,767 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$44,998
Medicare patients
280
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa47$901,730
Dupixent PenDupilumab135$646,485
SkyriziRisankizumab-Rzaa16$291,628
Taltz AutoinjectorIxekizumab28$205,848
OtezlaApremilast27$156,050
Cosentyx Sensoready (2 Pens)Secukinumab13$103,451
Dupixent SyringeDupilumab19$85,296
ZoryveRoflumilast12$10,540
Clindamycin Phosphate56$4,209
Fluorouracil66$4,201
Ketoconazole210$3,595
Tacrolimus32$3,561
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc38$2,664
Metronidazole42$2,395
Betamethasone Dipropionate25$2,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$81$291,62816 claims
AmgenOtezla$158$156,05027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →